The Role of TRP Channels in DPN

NCT ID: NCT07237022

Last Updated: 2025-11-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-10-08

Study Completion Date

2026-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims to characterize the vascular response upon topical application of cinnamaldehyde, allyl isothiocyanate and capsaicin on feet skin in healthy volunteers. The vascular response will be characterized in terms of response over time, dose-response, inter-foot and inter-period reproducibility.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Physiological Responses

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cinnamaldehyde

A 10% and 30% cinnamaldehyde solution is topically applied on foot skin.

Intervention Type OTHER

Allyl isothiocyanate (AITC)

A 15% and up to 30% AITC solution is topically applied on foot skin.

Intervention Type OTHER

Capsaicin

A 1.5% and 5% capsaicin solution is topically applied on foot skin.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is a white male or female ≥18 and ≤45 years of age
2. Subject is a non-smoker for at least 6 months prior to the start of the study
3. Subject has a body mass index (BMI) between 18-30 kg/m²
4. Subject is judged to be in good general health on the basis of medical history, physical examination and vital signs
5. Subject understands the procedures and agrees to participate in the study by giving written informed consent.

Exclusion Criteria

1. Subject has a history of any illness or disorder which, in the investigator's opinion, might confound the results of the study
2. Subject has a history of significant severe (drug) allergies
3. Subject is a female who is pregnant, breast-feeding or intends to become pregnant, or is of child-bearing potential and is not using an adequate contraceptive method
4. Subject uses any prescription or non-prescription drugs on a regular basis which, in the investigator's opinion, might confound the results of the study
5. Subject currently uses lotions, oils, depilatory preparations, makeup, or other topical treatments on the feet on a regular basis which cannot be discontinued for the duration of the study
6. Subject has eczema, scleroderma, psoriasis, dermatitis or keloids, tumors, ulcers, burns, skin flaps or grafts on the volar surface of the forearm or the dorsum of the feet, or any other skin abnormality that, in the opinion of the investigator, may interfere with the study assessments
7. Subject has excessive hair growth on the volar surface of the forearms or the dorsum of the feet
8. Subject has any of the following vital sign measurements at screening after at least 10 minutes of supine rest: Heart Rate \<40 or \>100 beats/min, Diastolic Blood Pressure \<50 or \>90 mmHg, Systolic Blood Pressure \<90 or \>140 mmHg
9. Subject is unable to refrain from drinking caffeinated beverages (e.g. coffee, tea, cola, …) 24 hours prior to each study visit. Subject is unable to limit their intake of caffeinated beverages to ≤4 cups a day throughout the study
10. Subject is unable to refrain from drinking alcohol 24 hours prior to each study visit, is currently a regular user of illegal drugs, or has a history of substance abuse (including alcohol)
11. Subject is currently participating or has been involved in testing an investigational drug in another clinical study within the last 4 weeks
12. Subject is in a situation or has a condition which, in the opinion of the investigator, may interfere with safe and optimal participation in the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universitaire Ziekenhuizen KU Leuven

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Center for Clinical Pharmacology

Leuven, , Belgium

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Heleen Marynissen

Role: CONTACT

+3216347014

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Heleen Marynissen

Role: primary

+3216347014

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CCP24-3303-DPN

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Transient Receptor Potential Channels
NCT06444594 RECRUITING EARLY_PHASE1
ACD440 Gel in Peripheral Neuropathic Pain
NCT05416931 COMPLETED PHASE2